Date: April 22, 2021
Time: 10:00am (CEST), 4:00pm (CST)
Advancements in technologies have revolutionized the genetic landscape. Chromosomal microarray analysis (CMA) becomes a proven method and is implemented to detect gains and losses of DNA and absence of heterozygosity across the genome. Next-generation sequencing technologies have brought opportunities and challenges to genetic testing, its prenatal application is an emerging field. We describe our experience using FetalChip, a CMA for prenatal research developed in our laboratory and describe the role of CMA in the era of genome sequencing.
- The role of chromosomal microarray analysis (CMA) in prenatal genetic clinical research.
- CMA is a well-established and proven technology to identify pathogenic CNVs
- The utility of genome sequencing
For Research Use Only. Not for use in diagnostic procedures.
Webinars will be available for unlimited on-demand viewing after live event.